Researcher

Title

• Associate Professor, Department of Pharmacology and Physiology, Université de Montréal 
• Principal investigator, Centre de recherche Azrieli du CHU Sainte-Justine
• Director of drug screening platform, Centre de recherche Azrieli du CHU Sainte-Justine

• Postdoctoral training, MD Anderson Cancer Center, Department of Leukemia, University of Texas and Fels Institute for Cancer Research and Molecular Biology, Temple University (2009-2013) 
• Ph.D. in Biology, INRS-Institut Armand-Frappier, Université du Québec (2003-2008)
• M.Sc. in Biology, Université du Québec à Montréal (2001-2003)
• Undergraduate studies in Biochemistry, Université de Montpellier (2000)

Lab research interests

• Epigenetic therapy of pediatric cancers
• Epigenetic drug screening
• 3D cell culture

Lab members

• Mariya Kryvoshey, Master's Student
• Emmanuel Sy, Master's Student
• Walid Mardhy, Master's Student
• Anaïs Darracq, Postdoctoral Fellow
• Marielle Huot, Research Assistant
• Nicolas Sgarioto, Research Assistant

Publications

1. Anaïs Darracq, Nicolas Sgarioto, Marielle Huot, Gabrielle McInnes, Elisa Clement, Antoine Meant, Alexandra Langford, Oscar Villareal, François Marois, Maxime Caron, Pascal Saint-Onge, Severine Leclerc, Gaël Cagnone, Gregor Andelfinger, Daniel Sinnett, Stéphane Richard, Serge McGraw & Noël J-M Raynal. Time-dependant transcriptomic and epigenomic maturation of 3D cancer spheroids to better replicate tumours in situ and drug screenings. Pre-pring BioRxIV: doi: 10.1101/2025.01.23.634518 (2025).
2. Agata Mostkowska, Guy Rousseau, Noël J-M Raynal. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases. The FASEB Journal (2024).
3. Annie Beaudry, Simon Jacques-Ricard, Nicolas Sgarioto, Araceli Garcia, Teresita Rode García, William Lemieux, Kathie Béland, Elie Haddad, Paulo Cordeiro, Michel Duval, Serge McGraw, Chantal Richer, Maxime Caron, François Marois, Pascal St-Onge, Daniel Sinnett, Xavier Banquy, and Noël J-M Raynal. Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion. Scientific Reports (2023).
4. Dina Baier, Walter Berger, Theresa Mendrina, Beatrix Schoenhacker-Alte, Christine Pirker, Thomas Mohr, Mate Rusz, Benedikt Regner, Martin Schaier, Nicolas Sgarioto, Noël J-M Raynal, Karin Nowikovsky, Wolfgang Schmidt, Gunda Koellensperger, Samuel Meier-Menches, Petra Heffeter, Bernhard Keppler. The lipid metabolism as target and modulator of BOLD-100 anticancer activity: crosstalk with histone acetylation. Advanced Science (2023).
5. Somnath Pandey, Rahinatou Djibo, Anaïs Darracq, Gennaro Calendo, Hanghang Zhang, Ryan A. Henry, Andrew J. Andrews, Steven Baylin, Jozef Madzo, Rafael Najmanovich, Jean-Pierre J. Issa & Noël J.M. Raynal. Selective CDK9 inhibition by natural compound toyocamycin in cancer cells. Cancers (2022).
6. Marielle Huot, Maxime Caron, Chantal Richer, Rahinatou Djibo, Rafael Najmanovich, Pascal St-Onge, Daniel Sinnett & Noël J.M. Raynal. Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. Cancer Chemotherapy and Pharmacology (2021).
7. Claudia Dominici, Nicolas Sgarioto, Zhenbao Yu, Laura Sesma-Sanz, Jean-Yves Masson, Stéphane Richard and Noël J-M Raynal. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Clinical Epigenetics (2021).
8. J. Abusarah, Y. Cui, N. EL-Hachem, AE El-Kadiry, I Hammond-Martel, H. Wurtele, A. Beaudry, Noël J-M Raynal, F. Robert, J. Pelletier, M. Jankovic, F. Mercier, S. Kamyabiazar, B. Annabi, and M. Rafei. Tacima-218: A Novel Pro-Oxidant Agent Exhibiting Selective Anti-Tumoral Activity. Molecular Cancer Therapeutics (2021).
9. Elodie Marie Da Costa; Gregory Armaos; Gabrielle McInnes; Annie Beaudry; Gaël Moquin-Beaudry; Virginie Bertrand-Lehouillier; Maxime Caron; Chantal Richer; Pascal St-Onge; Jeffrey R. Johnson; Nevan Krogan; Yuka Sai; Michael Downey; Moutih Rafei; Meaghan Boileau; Kolja Eppert; Ema Flores-Díaz; André Haman; Trang Hoang; Daniel Sinnett; Christian Beauséjour; Serge McGraw and  Noël J-M Raynal. Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation. Journal of Experimental & Clinical Cancer Research, (2019).
10. Hanghang Zhang, Somnath Pandey, Meghan Travers, Hongxing Sun, George Morton, Jozef Madzo, Woonbok Chung, Jittasak Khowsathit, Oscar Perez-Leal, Carlos A. Barrero, Carmen Merali, Yasuyuki Okamoto, Takahiro Sato, Joshua Pan, Judith Garriga, Natarajan V. Bhanu, Johayra Simithy, Bela Patel, Jian Huang, Noël J.-M. Raynal, Benjamin A. Garcia, Marlene A. Jacobson, Cigall Kadoch, Salim Merali, Yi Zhang, Wayne Childers, Magid Abou-Gharbia, John Karanicolas, Stephen B. Baylin, Cynthia A. Zahnow, Jaroslav Jelinek, Xavier Grana, and Jean-Pierre J. Issa. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell (2018).
11. Elodie M. Da Costa, Gabrielle McInnes, Annie Beaudry, and Noël J.-M. Raynal, DNA methylation targeted drugs. The Cancer Journal: The Journal of Principles & Practice of Oncology (2017).
12. Noël J-M Raynal, Elodie Da Costa, Justin Lee, Gabriel Malouf, Sarah Dumont, Vazganush Gharibyan, Saira Ahmed, and Jean-Pierre J. Issa. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Molecular Cancer Therapeutics (2017).